Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red de Cáncer (19)

2024

  1. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

    The Lancet

  2. Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab

    Breast Cancer Research and Treatment

2023

  1. Analysis of tumor infiltrating CD4+ and CD8+ CDR3 sequences reveals shared features putatively associated to the anti-tumor immune response

    Frontiers in Immunology, Vol. 14

  2. Chromatin insulation orchestrates matrix metalloproteinase gene cluster expression reprogramming in aggressive breast cancer tumors

    Molecular Cancer, Vol. 22, Núm. 1

  3. Evaluation of triple negative breast cancer with heterogeneous immune infiltration

    Frontiers in Immunology, Vol. 14

  4. Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 1, pp. 67-80

2022

  1. Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study

    BMC Cancer, Vol. 22, Núm. 1

  2. Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer

    Cancer research, Vol. 82, Núm. 24, pp. 4670-4679

2021

  1. Epstein–Barr Virus+ B Cells in Breast Cancer Immune Response: A Case Report

    Frontiers in Immunology, Vol. 12

  2. Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer

    European Journal of Cancer, Vol. 148, pp. 134-145

  3. Obesity and Breast Cancer: A Paradoxical and Controversial Relationship Influenced by Menopausal Status

    Frontiers in Oncology, Vol. 11

2020

  1. Enhancing global access to cancer medicines

    CA Cancer Journal for Clinicians, Vol. 70, Núm. 2, pp. 105-124

  2. The second generation antibody-drug conjugate syd985 overcomes resistances to T-DM1

    Cancers, Vol. 12, Núm. 3

2019

  1. Clinical implications of extracellular HMGA1 in breast cancer

    International Journal of Molecular Sciences, Vol. 20, Núm. 23

  2. The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer

    Cell Reports, Vol. 27, Núm. 9, pp. 2690-2708.e10

2018

  1. MSK1 regulates luminal cell differentiation and metastatic dormancy in ER + breast cancer

    Nature Cell Biology, Vol. 20, Núm. 2, pp. 211-221

  2. Erratum to: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer (Nature Cell Biology, (2018), 20, 2, (211-221), 10.1038/s41556-017-0021-z)

    Nature Cell Biology

  3. Extracellular HMGA1 promotes tumor invasion and metastasis in triple-negative breast cancer

    Clinical Cancer Research, Vol. 24, Núm. 24, pp. 6367-6382

  4. P95HER2–T cell bispecific antibody for breast cancer treatment

    Science Translational Medicine, Vol. 10, Núm. 461